Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis
Henry S. Cheng, Daniel Pérez-Cremades, Rulin Zhuang, Anurag Jamaiyar, Winona Wu, Jingshu Chen, Aspasia Tzani, Lauren Stone, Jorge Plutzky, Terence E. Ryan, Philip P. Goodney, Mark A. Creager, Marc S. Sabatine, Marc P. Bonaca, Mark W. Feinberg
Henry S. Cheng, Daniel Pérez-Cremades, Rulin Zhuang, Anurag Jamaiyar, Winona Wu, Jingshu Chen, Aspasia Tzani, Lauren Stone, Jorge Plutzky, Terence E. Ryan, Philip P. Goodney, Mark A. Creager, Marc S. Sabatine, Marc P. Bonaca, Mark W. Feinberg
View: Text | PDF
Research Article Angiogenesis Vascular biology

Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis

  • Text
  • PDF
Abstract

Patients with peripheral artery disease (PAD) and diabetes compose a high-risk population for development of critical limb ischemia (CLI) and amputation, although the underlying mechanisms remain poorly understood. Comparison of dysregulated microRNAs from diabetic patients with PAD and diabetic mice with limb ischemia revealed the conserved microRNA, miR–130b-3p. In vitro angiogenic assays demonstrated that miR-130b rapidly promoted proliferation, migration, and sprouting in endothelial cells (ECs), whereas miR-130b inhibition exerted antiangiogenic effects. Local delivery of miR-130b mimics into ischemic muscles of diabetic mice (db/db) following femoral artery ligation (FAL) promoted revascularization by increasing angiogenesis and markedly improved limb necrosis and amputation. RNA-Seq and gene set enrichment analysis from miR-130b–overexpressing ECs revealed the BMP/TGF-β signaling pathway as one of the top dysregulated pathways. Accordingly, overlapping downregulated transcripts from RNA-Seq and miRNA prediction algorithms identified that miR-130b directly targeted and repressed the TGF-β superfamily member inhibin-β-A (INHBA). miR-130b overexpression or siRNA-mediated knockdown of INHBA induced IL-8 expression, a potent angiogenic chemokine. Lastly, ectopic delivery of silencer RNAs (siRNA) targeting Inhba in db/db ischemic muscles following FAL improved revascularization and limb necrosis, recapitulating the phenotype of miR-130b delivery. Taken together, a miR-130b/INHBA signaling axis may provide therapeutic targets for patients with PAD and diabetes at risk of developing CLI.

Authors

Henry S. Cheng, Daniel Pérez-Cremades, Rulin Zhuang, Anurag Jamaiyar, Winona Wu, Jingshu Chen, Aspasia Tzani, Lauren Stone, Jorge Plutzky, Terence E. Ryan, Philip P. Goodney, Mark A. Creager, Marc S. Sabatine, Marc P. Bonaca, Mark W. Feinberg

×

Figure 1

Identification of miR–130b-3p in experimental PAD in diabetic mice and in patients with PAD and diabetes.

Options: View larger image (or click on image) Download as PowerPoint
Identification of miR–130b-3p in experimental PAD in diabetic mice and i...
(A) Venn diagram indicating number of miRNAs commonly dysregulated from human and mouse miRNA-Seq analysis (F, Fontaine; Db, diabetes). (B) Normalized counts of miR-130b in patients with PAD and with or without diabetes or limb events (n = 6–7). (C) Normalized counts of miR-130b in plasma from a separate cohort of patients with PAD compared with plasma from healthy individuals (n = 6). (D) (Left) Volcano plot highlighting miR-130b in muscles from patients with PAD compared with healthy individuals. (Right) Normalized counts of miR-130b in muscles of patients with PAD compared with healthy individuals (n = 7). (E) miR-130b expression normalized to U6 in ischemic gastrocnemius of db/+ and db/db mice at different time points after FAL. Comparison between groups at specific time points by unpaired Student’s t test (d0, n = 11–12; d3, n = 7–12; d11, n = 5–6; d31, n = 4–7). (F–H) Relative expression of miR-130b normalized to U6 in HUVECs under different conditions: after 72 hours of D-glucose compared with mannitol control (n = 5–6) (F); after 3 or 24 hours of VEGF-A stimulation (n = 3) (G); or after 4, 16, and 24 hours of 2% hypoxia compared with normoxia control (n = 3-4) (H), performed with 2-way ANOVA. (I) Representative immunofluorescence images of human skeletal muscles from patients with diabetes and PAD stained for miR–130b-3p (green), CD31 (red), DAPI (blue), and merged, with arrows indicating colocalization. Scale bar: 50 μm. Statistics performed using unpaired 2-tailed Student’s t test unless stated otherwise. *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts